Histiocytic disorders

KL McClain, C Bigenwald, M Collin… - Nature Reviews …, 2021 - nature.com
The historic term 'histiocytosis' meaning 'tissue cell'is used as a unifying concept for
diseases characterized by pathogenic myeloid cells that share histological features with …

Langerhans cell histiocytosis

C Rodriguez-Galindo, CE Allen - Blood, The Journal of the …, 2020 - ashpublications.org
Langerhans cell histiocytosis (LCH) is caused by clonal expansion of myeloid precursors
that differentiate into CD1a+/CD207+ cells in lesions that leads to a spectrum of organ …

Diverse and targetable kinase alterations drive histiocytic neoplasms

EL Diamond, BH Durham, J Haroche, Z Yao, J Ma… - Cancer discovery, 2016 - AACR
Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation
of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell …

[HTML][HTML] Histopathologic review of granulomatous inflammation

KK Shah, BS Pritt, MP Alexander - Journal of clinical tuberculosis and other …, 2017 - Elsevier
Granulomatous inflammation is a histologic pattern of tissue reaction which appears
following cell injury. Granulomatous inflammation is caused by a variety of conditions …

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis

R Chakraborty, OA Hampton, X Shen… - Blood, The Journal …, 2014 - ashpublications.org
Langerhans cell histiocytosis (LCH) is a myeloproliferative disorder characterized by lesions
composed of pathological CD207+ dendritic cells with an inflammatory infiltrate …

Langerhans-cell histiocytosis

CE Allen, M Merad, KL McClain - New England Journal of …, 2018 - Mass Medical Soc
Langerhans-Cell Histiocytosis A spectrum of diseases formerly known as histiocytosis X and
now called Langerhans-cell histiocytosis is characterized by ERK pathway activation …

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

ML Berres, KPH Lim, T Peters, J Price… - Journal of Experimental …, 2014 - rupress.org
Langerhans cell histiocytosis (LCH) is a clonal disorder with elusive etiology, characterized
by the accumulation of CD207+ dendritic cells (DCs) in inflammatory lesions. Recurrent …

Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

H Gadner, M Minkov, N Grois… - Blood, The Journal …, 2013 - ashpublications.org
Langerhans cell histiocytosis (LCH)-III tested risk-adjusted, intensified, longer treatment of
multisystem LCH (MS-LCH), for which optimal therapy has been elusive. Stratified by risk …

Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment

M Kobayashi, A Tojo - Cancer science, 2018 - Wiley Online Library
Langerhans cell histiocytosis (LCH) is a rare systemic disorder characterized by the
accumulation of CD 1a+/Langerin+ LCH cells and wide‐ranging organ involvement …

How I treat Langerhans cell histiocytosis

CE Allen, S Ladisch, KL McClain - Blood, The Journal of the …, 2015 - ashpublications.org
Abstract “Langerhans cell histiocytosis”(LCH) describes a spectrum of clinical presentations
ranging from a single bone lesion or trivial skin rash to an explosive disseminated disease …